| 2.78 0.25 (9.88%) | 10-09 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 4.86  |
1-year : | 6.06 |
| Resists | First : | 4.16 |
Second : | 5.19 |
| Pivot price | 3.09 |
|||
| Supports | First : | 2.5 |
Second : | 2.08 |
| MAs | MA(5) : | 2.78 |
MA(20) : | 3.16 |
| MA(100) : | 4.09 |
MA(250) : | 6.57 |
|
| MACD | MACD : | -0.4 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 10.6 |
D(3) : | 8.3 |
| RSI | RSI(14): 38.8 |
|||
| 52-week | High : | 12.09 | Low : | 2.5 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ NTHI ] has closed above bottom band by 20.0%. Bollinger Bands are 29.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.84 - 2.85 | 2.85 - 2.87 |
| Low: | 2.46 - 2.48 | 2.48 - 2.5 |
| Close: | 2.75 - 2.78 | 2.78 - 2.81 |
NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company. It develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company was founded in 2008 and is headquartered in Calabasas, CA.
Thu, 08 Oct 2026
NeOnc Technologies Holdings, Inc. (NTHI) Stock Price, News, Quote & History - Yahoo! Finance Canada
Tue, 06 Oct 2026
In a brain cancer study, 48.9% were alive without worsening disease at six months. - Stock Titan
Mon, 28 Sep 2026
NeOnc Technologies Holdings Sets November 17 FDA End-of-Phase 1 Meeting for Brain-Cancer Drug NEO212 - Quiver Quantitative
Mon, 28 Sep 2026
NeOnc Technologies Announces FDA End of Phase 1 Meeting for NEO212 - Stock Titan
Mon, 28 Sep 2026
NeOnc Technologies Announces FDA End of Phase 1 Meeting for NEO212 - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 26 (M) |
| Held by Insiders | 8.08e+006 (%) |
| Held by Institutions | 58.9 (%) |
| Shares Short | 522 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -104 % |
| Return on Assets (ttm) | 418.8 % |
| Return on Equity (ttm) | -635 % |
| Qtrly Rev. Growth | 39990 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -2.2 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -21 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -0 |
| Dividend | 0 |
| Forward Dividend | 597820 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|